MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- FRESENIUS KABI ONCO. - ASTRAZENECA PHARMA
FRESENIUS KABI ONCO. vs ASTRAZENECA PHARMA - Comparison Results
FRESENIUS KABI ONCO. Change
Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More
ASTRAZENECA PHARMA 
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
Current Valuations
| FRESENIUS KABI ONCO. | ASTRAZENECA PHARMA | FRESENIUS KABI ONCO./ ASTRAZENECA PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 22.1 | 101.6 | 21.8% | View Chart |
| P/BV | x | 3.1 | 28.6 | 10.9% | View Chart |
| Dividend Yield | % | 0.0 | 0.0 | - |
Financials
 FRESENIUS KABI ONCO.  ASTRAZENECA PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| FRESENIUS KABI ONCO. Mar-13 |
ASTRAZENECA PHARMA Mar-18 |
FRESENIUS KABI ONCO./ ASTRAZENECA PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 176 | 1,278 | 13.8% | |
| Low | Rs | 79 | 883 | 8.9% | |
| Sales per share (Unadj.) | Rs | 37.7 | 228.4 | 16.5% | |
| Earnings per share (Unadj.) | Rs | 5.1 | 10.4 | 49.1% | |
| Cash flow per share (Unadj.) | Rs | 6.7 | 16.3 | 41.3% | |
| Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
| Dividend yield (eoy) | % | 0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 42.5 | 98.8 | 43.1% | |
| Shares outstanding (eoy) | m | 158.23 | 25.00 | 632.9% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 3.4 | 4.7 | 71.4% | |
| Avg P/E ratio | x | 25.0 | 104.2 | 24.0% | |
| P/CF ratio (eoy) | x | 18.9 | 66.4 | 28.5% | |
| Price / Book Value ratio | x | 3.0 | 10.9 | 27.3% | |
| Dividend payout | % | 0 | 0 | - | |
| Avg Mkt Cap | Rs m | 20,135 | 27,008 | 74.6% | |
| No. of employees | `000 | 1.2 | 1.4 | 85.0% | |
| Total wages/salary | Rs m | 703 | 1,535 | 45.8% | |
| Avg. sales/employee | Rs Th | 5,176.2 | 4,210.9 | 122.9% | |
| Avg. wages/employee | Rs Th | 610.4 | 1,132.2 | 53.9% | |
| Avg. net profit/employee | Rs Th | 699.6 | 191.1 | 366.1% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,963 | 5,710 | 104.4% | |
| Other income | Rs m | 18 | 123 | 14.7% | |
| Total revenues | Rs m | 5,981 | 5,833 | 102.5% | |
| Gross profit | Rs m | 1,430 | 463 | 308.9% | |
| Depreciation | Rs m | 258 | 147 | 175.0% | |
| Interest | Rs m | -26 | 0 | - | |
| Profit before tax | Rs m | 1,216 | 438 | 277.7% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -68 | 0 | - | |
| Tax | Rs m | 342 | 179 | 191.3% | |
| Profit after tax | Rs m | 806 | 259 | 311.0% | |
| Gross profit margin | % | 24.0 | 8.1 | 295.8% | |
| Effective tax rate | % | 28.1 | 40.8 | 68.9% | |
| Net profit margin | % | 13.5 | 4.5 | 297.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 5,102 | 3,209 | 159.0% | |
| Current liabilities | Rs m | 2,385 | 2,070 | 115.3% | |
| Net working cap to sales | % | 45.6 | 20.0 | 228.2% | |
| Current ratio | x | 2.1 | 1.6 | 137.9% | |
| Inventory Days | Days | 150 | 72 | 207.4% | |
| Debtors Days | Days | 113 | 35 | 324.4% | |
| Net fixed assets | Rs m | 5,148 | 790 | 651.4% | |
| Share capital | Rs m | 158 | 50 | 316.4% | |
| "Free" reserves | Rs m | 6,556 | 2,419 | 271.0% | |
| Net worth | Rs m | 6,732 | 2,469 | 272.6% | |
| Long term debt | Rs m | 952 | 0 | - | |
| Total assets | Rs m | 10,388 | 4,605 | 225.6% | |
| Interest coverage | x | -45.8 | NM | - | |
| Debt to equity ratio | x | 0.1 | 0 | - | |
| Sales to assets ratio | x | 0.6 | 1.2 | 46.3% | |
| Return on assets | % | 7.5 | 5.6 | 133.4% | |
| Return on equity | % | 12.0 | 10.5 | 114.1% | |
| Return on capital | % | 14.6 | 17.7 | 82.3% | |
| Exports to sales | % | 74.5 | 0 | - | |
| Imports to sales | % | 24.8 | 0 | - | |
| Exports (fob) | Rs m | 4,441 | NA | - | |
| Imports (cif) | Rs m | 1,477 | NA | - | |
| Fx inflow | Rs m | 5,298 | 300 | 1,768.5% | |
| Fx outflow | Rs m | 1,772 | 2,015 | 88.0% | |
| Net fx | Rs m | 3,525 | -1,715 | -205.5% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,274 | 88 | 1,449.5% | |
| From Investments | Rs m | -1,204 | -94 | 1,286.5% | |
| From Financial Activity | Rs m | -196 | NA | - | |
| Net Cashflow | Rs m | -126 | -6 | 2,215.8% | |
Share Holding
| Indian Promoters | % | 0.0 | 0.0 | - | |
| Foreign collaborators | % | 81.0 | 75.0 | 108.0% | |
| Indian inst/Mut Fund | % | 0.3 | 0.3 | 100.0% | |
| FIIs | % | 9.6 | 15.7 | 61.1% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 9.1 | 9.1 | 100.0% | |
| Shareholders | 42,599 | 12,856 | 331.4% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare FRESENIUS KABI ONCO. With: DR. DATSONS LABS BIOCON J.B.CHEMICALS JUBILANT LIFE SCIENCES AJANTA PHARMA
Compare FRESENIUS KABI ONCO. With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Opens Flat; Sun Pharma and ITC Top Losers(09:30 am)
Asian stock markets are mixed today. The Nikkei 225 is flat while the Hang Seng is down 0.3%. The Shanghai Composite is trading up by 0.1%.
Related Views on News
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Mar 29, 2019 | Updated on Mar 29, 2019Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.
ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)
Nov 27, 2018 | Updated on Nov 27, 2018For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsMost Popular
Use My Secret to Increase Your Trading Profits Today
Dec 10, 2019What to do after every trade.
How We Made 14.64% Trading Profit in Just 2 Days
Dec 12, 2019A high probability trade that worked to perfection for my subscribers.
Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020(Profit Hunter)
Dec 5, 2019This corner of the market could provide more returns than blue chips in 2020.
Make the Most of the Smallcap Rebound with These Stocks(Profit Hunter)
Dec 3, 2019Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.
Stocks that Can Outperform No Matter what the RBI Does Today(The 5 Minute Wrapup)
Dec 5, 2019I won't be surprised if these stocks repeat their 2002-2006 performance.
MoreFRESENIUS KABI ONCO. SHARE PRICE
Jan 2, 2014 (Close)
TRACK FRESENIUS KABI ONCO.
- Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON FRESENIUS KABI ONCO.
FRESENIUS KABI ONCO. - DR. REDDYS LAB COMPARISON
COMPARE FRESENIUS KABI ONCO. WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.